In this free webinar, learn how simplifying supply chain management can accelerate the advancement of CRISPR-based therapies, reduce risk and ultimately bring therapies to market faster. Attendees ...

Type V and VI CRISPR/Cas systems have emerged as promising cutting-edge diagnostic tools for nucleic acid detection. Nevertheless, the challenge of low target concentrations necessitates ...

CRISPR/Cas systems have undergone tremendous advancement in the past decade. These precise genome editing tools have applications ranging from transgenic crop development to gene therapy and beyond.

Synthego’s CEO and co-founder Paul Dabrowski used to be lead digital designer at SpaceX. Now that he’s applying his engineering talents to intracellular space, he hopes to contribute to dramatic cost ...

CRISPR Therapeutics now has an approved product in its portfolio in Casgevy. The treatment has the potential to be a game changer for the company's business. Even with more treatments in its portfolio ...

Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

Going beyond pregnancy and COVID-19, the world could someday soon come to rely on at-home tests for many diseases thanks in part to AI-fueled improvements. University of Florida scientists have used ...

As in 2020, CRISPR still doesn't have an approved product -- but that could change soon. The stock has been volatile, providing investors with potential for both big gains and losses. But now that the ...